T-LGL
MCID: TCL002
MIFTS: 48

T-Cell Large Granular Lymphocyte Leukemia (T-LGL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for T-Cell Large Granular Lymphocyte Leukemia

MalaCards integrated aliases for T-Cell Large Granular Lymphocyte Leukemia:

Name: T-Cell Large Granular Lymphocyte Leukemia 12 20 58 15 70
Proliferation of Large Granular Lymphocytes 20 58
T-Cell Lgl Leukemia 20 58
T-Lgl 20 58
T-Cell Large Granular Lymphocyte Leukaemia 12
Large Cell Granular Lymphogenous Leukemia 20
Large Granular Lymphocytic Leukaemia 12
Leukemia, Large Granular Lymphocytic 70
Large Granular Lymphocytic Leukemia 12
Leukemia Lymphocytic Large Granular 54
T-Lgl Leukemia 20

Characteristics:

Orphanet epidemiological data:

58
t-cell large granular lymphocyte leukemia
Prevalence: 1-9/1000000 (Europe); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:0050751
NCIt 50 C4664
MESH via Orphanet 45 D054066
UMLS via Orphanet 71 C1955861 C2930809
Orphanet 58 ORPHA86872
UMLS 70 C1522378 C1955861

Summaries for T-Cell Large Granular Lymphocyte Leukemia

GARD : 20 T- cell large granular lymphocyte leukemia is a rare cancer of a type of white blood cells called lymphocytes. T-cell large granular lymphocyte leukemia causes a slow increase in white blood cells called T lymphocytes, or T cells, which originate in the lymph system and bone marrow and help to fight infection. This disease usually affects people in their sixties. Symptoms include anemia ; low levels of platelets ( thrombocytopenia ) and infection-fighting neutrophils ( neutropenia ) in the blood; and an enlarged spleen. About one-third of patients are asymptomatic at the time of diagnosis. The exact cause of LGL leukemia is unknown. Doctors can diagnose this disease through a bone marrow biopsy, or by using a specialized technique in which various types of blood or bone marrow cells are separated, identified, and counted.

MalaCards based summary : T-Cell Large Granular Lymphocyte Leukemia, also known as proliferation of large granular lymphocytes, is related to pure red-cell aplasia and lymphoproliferative syndrome. An important gene associated with T-Cell Large Granular Lymphocyte Leukemia is STAT3 (Signal Transducer And Activator Of Transcription 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Methotrexate and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A T-cell lymphocytic leukemia that exhibits an unexplained, chronic (greater than 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood.

Wikipedia : 73 Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an... more...

Related Diseases for T-Cell Large Granular Lymphocyte Leukemia

Diseases related to T-Cell Large Granular Lymphocyte Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 pure red-cell aplasia 31.0 STAT3 IL2RA IL2
2 lymphoproliferative syndrome 30.7 STAT3 IL2RA IL2 FASLG
3 felty syndrome 30.3 STAT3 CSF2 B3GAT1
4 adult t-cell leukemia 30.2 STAT3 IL2RA IL2
5 anaplastic large cell lymphoma 30.2 STAT3 IL2RA GZMB
6 virus associated hemophagocytic syndrome 30.2 IL2RB IL2
7 graft-versus-host disease 30.2 IL2 GZMB FASLG
8 hairy cell leukemia 30.1 IL2RB IL2RA IL2
9 lymphopenia 30.1 IL2RA IL2 FASLG
10 tropical spastic paraparesis 30.1 KIR2DL3 IL2RB IL2RA IL2
11 t-cell lymphoblastic leukemia/lymphoma 29.8 STAT3 IL2RB IL2RA IL2 FASLG
12 aggressive nk-cell leukemia 29.8 STAT3 NCAM1 KLRD1 GZMB FASLG B3GAT1
13 peripheral t-cell lymphoma 29.7 STAT3 NCAM1 IL2RB IL2 GZMB
14 hemophagocytic lymphohistiocytosis 29.6 IL2RA IL18 GZMB
15 common variable immunodeficiency 29.6 STAT3 IL2RB IL2RA IL2 GZMB
16 aspergillosis 29.6 STAT3 IL18 CSF2
17 myeloma, multiple 29.5 STAT3 NCAM1 KLRK1 IL2 CSF2
18 lymphoma, hodgkin, classic 29.5 IL2RA IL2 GZMB CSF2
19 leukemia, chronic lymphocytic 29.4 STAT3 NCAM1 IL2RA IL2 CSF2
20 myelodysplastic syndrome 29.4 STAT5B STAT3 KLRK1 IL2 GZMB FASLG
21 peripheral nervous system disease 29.4 STAT3 NCAM1 IL2 CSF2
22 crohn's disease 29.3 STAT3 IL2RA IL2 IL18 CSF2
23 severe combined immunodeficiency 29.2 STAT5B IL2RB IL2RA IL2 CSF2
24 viral infectious disease 29.2 KLRK1 IL2RA IL2 IL18 GZMB
25 rheumatoid arthritis 29.2 IL2RB IL2RA IL2 IL18 FASLG CSF2
26 thrombocytopenia 29.1 STAT3 IL2 IL18 GZMB FASLG CSF2
27 aplastic anemia 29.1 STAT3 IL2RA IL2 IL18 FASLG CSF2
28 combined immunodeficiency 29.1 STAT5B STAT3 KLRK1 IL2RB IL2RA IL2
29 celiac disease 1 29.0 STAT3 NCAM1 KLRK1 KLRD1 IL2RA IL2
30 renal cell carcinoma, nonpapillary 28.9 STAT3 IL2RB IL2RA IL2 FASLG CSF2
31 autoimmune disease 28.7 STAT3 KLRK1 IL2RA IL2 IL18 FASLG
32 lymphoma, non-hodgkin, familial 28.6 STAT3 NCAM1 IL2RB IL2RA IL2 GZMB
33 systemic lupus erythematosus 28.5 STAT3 IL2RB IL2RA IL2 IL18 FASLG
34 leukemia, acute myeloid 28.5 STAT5B STAT3 NCAM1 KLRK1 KLRD1 KIR2DL3
35 immune deficiency disease 28.0 STAT5B LBR KLRK1 IL2RB IL2RA IL2
36 large granular lymphocyte leukemia 11.7
37 leukemia 10.9
38 neutropenia 10.7
39 splenomegaly 10.6
40 deficiency anemia 10.5
41 pancytopenia 10.4
42 hepatosplenic t-cell lymphoma 10.4
43 autoimmune enteropathy 10.3 STAT3 IL2RA
44 prolymphocytic leukemia 10.3
45 agammaglobulinemia 10.3
46 arthritis 10.3
47 granulocytopenia 10.3
48 t-cell prolymphocytic leukemia 10.3
49 anemia, autoimmune hemolytic 10.3
50 heavy chain disease 10.3

Graphical network of the top 20 diseases related to T-Cell Large Granular Lymphocyte Leukemia:



Diseases related to T-Cell Large Granular Lymphocyte Leukemia

Symptoms & Phenotypes for T-Cell Large Granular Lymphocyte Leukemia

GenomeRNAi Phenotypes related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 9.98 STAT5B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 9.98 IL18
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.98 STAT5B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.98 STAT5B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.98 KIR2DL1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 9.98 KIR2DL1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.98 STAT5B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.98 KIR2DL1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 9.98 KIR2DL1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 9.98 STAT5B
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-3 9.98 STAT5B
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.98 IL18
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 9.98 IL18
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 9.98 IL2RB STAT5B
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-5 9.98 KIR2DL1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.98 IL2RB
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 9.98 IL18
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.98 IL18
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 9.98 KIR2DL1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-83 9.98 KIR2DL1
21 Reduced mammosphere formation GR00396-S 9.17 FASLG IL15RA IL2RA KLRD1 KLRK1 NCAM1

MGI Mouse Phenotypes related to T-Cell Large Granular Lymphocyte Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 CSF2 FASLG IL15RA IL2 IL2RA IL2RB
2 hematopoietic system MP:0005397 9.73 CSF2 FASLG GZMA GZMK IL15RA IL18
3 immune system MP:0005387 9.44 CSF2 FASLG GZMA GZMK IL15RA IL18

Drugs & Therapeutics for T-Cell Large Granular Lymphocyte Leukemia

Drugs for T-Cell Large Granular Lymphocyte Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
2
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
3
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
4
Thalidomide Approved, Investigational, Withdrawn Phase 2, Phase 3 50-35-1 5426
5 Folic Acid Antagonists Phase 2, Phase 3
6
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
7
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
8
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
9
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
10
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
11
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
12
Busulfan Approved, Investigational Phase 2 55-98-1 2478
13
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
14
alemtuzumab Approved, Investigational Phase 2 216503-57-0
15
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
16
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
17
Lenalidomide Approved Phase 2 191732-72-6 216326
18
rituximab Approved Phase 2 174722-31-7 10201696
19
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
20
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
21
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
22
tipifarnib Investigational Phase 2 192185-72-1 159324
23 Methylprednisolone Acetate Phase 2
24 Rho(D) Immune Globulin Phase 2
25 Neuroprotective Agents Phase 2
26 Antilymphocyte Serum Phase 2
27 gamma-Globulins Phase 2
28 Thymoglobulin Phase 2
29 Antiviral Agents Phase 2
30 Dermatologic Agents Phase 2
31 Antineoplastic Agents, Immunological Phase 2
32 Immunoglobulins Phase 2
33 Antibodies Phase 2
34 Antibodies, Monoclonal Phase 2
35 Angiogenesis Inhibitors Phase 2
36 Cyclosporins Phase 2
37 Antifungal Agents Phase 2
38 Liver Extracts Phase 2
39 Protein Kinase Inhibitors Phase 2
40 Immunoglobulins, Intravenous Phase 1, Phase 2
41 Immunoconjugates Phase 1, Phase 2
42 Cola Phase 1, Phase 2
43
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
44
Dasatinib Approved, Investigational Phase 1 302962-49-8 3062316
45
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
46
Bevacizumab Approved, Investigational Phase 1 216974-75-3
47
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
48
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
49
Etoposide Approved Phase 1 33419-42-0 36462
50
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Thalidomide Plus Prednisone and Methotrexate for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Multicenter Clinical Trial From China Recruiting NCT04453345 Phase 2, Phase 3 thalidomide + prednisone + methotrexate
2 Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia Unknown status NCT01976182 Phase 2 Methotrexate;Cyclophosphamide
3 A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma Unknown status NCT03239392 Phase 1, Phase 2 BNZ132-1-40
4 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
5 Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia Completed NCT00031980 Phase 2 cyclosporine
6 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
7 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
8 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
9 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
10 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
11 Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial Completed NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
12 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
13 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
14 Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath) Completed NCT00345345 Phase 2
15 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
16 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Active, not recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
17 First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL) Terminated NCT00278265 Phase 2 MTX followed by fludarabine
18 Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL) Terminated NCT01191749 Phase 2 Alemtuzumab
19 Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia Terminated NCT00363779 Phase 2 Cyclosporine
20 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
21 A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
22 A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia Terminated NCT00360776 Phase 2 tipifarnib
23 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Terminated NCT01805037 Phase 1, Phase 2 brentuximab vedotin
24 A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA Terminated NCT01769222 Phase 1, Phase 2
25 Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
26 Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia Completed NCT00076180 Phase 1
27 PHASE I STUDY OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA USING THE MIK-BETA 1 MONOCLONAL ANTIBODY DIRECTED TOWARD THE IL-2R BETA SUBUNIT Completed NCT00019032 Phase 1
28 Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies Completed NCT01567709 Phase 1 Alisertib;Vorinostat
29 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00608361 Phase 1 Dasatinib
30 Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors Completed NCT01748721 Phase 1
31 Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma Completed NCT01129180 Phase 1 azacitidine;bortezomib
32 A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy Completed NCT00890747 Phase 1 sunitinib malate
33 A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies Completed NCT01254578 Phase 1 Lenalidomide
34 A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
35 Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies Completed NCT00458731 Phase 1 cediranib maleate
36 A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
37 Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine Completed NCT00001533 Phase 1 cyclosporine
38 A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
39 Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma Active, not recruiting NCT02168140 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
40 A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma Terminated NCT00671112 Phase 1 Bortezomib;Everolimus
41 A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies Terminated NCT01678443 Phase 1
42 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
43 A Phase I Trial of the Combination of Oxaliplatin (NSC 266046, IND 57004), Ifosfamide, and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas Terminated NCT00101205 Phase 1 oxaliplatin;etoposide
44 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors Completed NCT00898079
45 Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function Completed NCT01199562 ganciclovir;valganciclovir;foscarnet sodium
46 The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer Completed NCT01053494
47 Personalized Monitoring of Intravenous Busulfan Dosing for Patients With Lymphoma Undergoing Autologous Stem Cell Transplantation. Completed NCT01959477 Early Phase 1 busulfan;etoposide;cyclophosphamide
48 Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine and/or Low Dose TBI With Disease-Risk Based Immunosuppression Completed NCT00014235 fludarabine phosphate;cyclosporine;mycophenolate mofetil
49 Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00112593 fludarabine phosphate;cyclosporine;mycophenolate mofetil
50 Low-Dose TBI and Fludarabine Followed by Unrelated Donor Stem Cell Transplantation for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial Completed NCT00005799 fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for T-Cell Large Granular Lymphocyte Leukemia

Genetic Tests for T-Cell Large Granular Lymphocyte Leukemia

Anatomical Context for T-Cell Large Granular Lymphocyte Leukemia

MalaCards organs/tissues related to T-Cell Large Granular Lymphocyte Leukemia:

40
Bone, Bone Marrow, T Cells, Spleen, Myeloid, Liver, Lymph Node

Publications for T-Cell Large Granular Lymphocyte Leukemia

Articles related to T-Cell Large Granular Lymphocyte Leukemia:

(show top 50) (show all 309)
# Title Authors PMID Year
1
Steady-State Design of Large-Dimensional Boolean Networks. 61
32287018 2021
2
Large granular lymphocyte leukaemia study at the University Hospital of Donostia. 61
33479020 2021
3
Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. 61
32348994 2021
4
FPGA Accelerated Analysis of Boolean Gene Regulatory Networks. 61
31494553 2020
5
Choroidal Infiltration as First Clinical Manifestation of T-cell Large Granular Lymphocyte (T-LGL) Leukemia. 61
31577464 2020
6
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations. 61
32659374 2020
7
Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations. 61
32710512 2020
8
Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission. 61
32614159 2020
9
[Clinical features and risk factors analyses of patients with T cell large granular lymphocytosis following allo-HSCT]. 61
32942815 2020
10
T cell lymphoma in the setting of Sjögren's syndrome: T cells gone bad? Report of five cases from a single centre cohort. 61
33025901 2020
11
Causes of double-negative T-cell lymphocytosis in children and adults. 61
31810993 2020
12
Hemolytic Anemia as Presentation of T-Cell Large Granular Lymphocytic Leukemia After Kidney Transplantation: A Case Report. 61
32505499 2020
13
Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies. 61
32035011 2020
14
Clonal T-cell large granular lymphocyte proliferations in childhood and young adult immune dysregulation conditions. 61
32124536 2020
15
High Incidence of Clonal CD8+ T-cell Proliferation in Non-malignant Conditions May Reduce the Significance of T-cell Clonality Assay for Differential Diagnosis in Oncohematology. 61
32046930 2020
16
[Clinical and laboratory characteristics in patients with myeloid neoplasms complicated with clonal T large granular lymphocyte proliferation]. 61
32447929 2020
17
Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. 61
32035354 2020
18
Retroviral sero-reactivity in LGL leukaemia patients and family members. 61
31608437 2020
19
[Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia]. 61
32135626 2020
20
Complete remission of aggressive T-cell LGL leukemia with pentostatin therapy: first case report. 61
33437844 2020
21
T-Cell Large Granular Lymphocyte Leukemia in a Patient With Rheumatoid Arthritis. 61
32646239 2020
22
STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. 61
30967617 2019
23
T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature. 61
31250283 2019
24
T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. 61
31585621 2019
25
Recurrent anti-GBM disease with T-cell large granular lymphocytic leukemia: A case report. 61
31374037 2019
26
Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath? 61
30652530 2019
27
Identification of regulatory variables for state transition of biological networks. 61
31071365 2019
28
Scalable optimal Bayesian classification of single-cell trajectories under regulatory model uncertainty. 61
31189480 2019
29
[CD4(-)/CD8(-)/CD56(+)/TCRγδ(+) T-cell large granular lymphocyte leukemia presenting as aplastic anemia: a case report and literature review]. 61
31340629 2019
30
IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. 61
30353031 2019
31
Immune dysregulation: EBV+ DLBCL and HLH in a patient with T-LGL. 61
30975643 2019
32
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization. 61
30573508 2019
33
Edgetic perturbations to eliminate fixed-point attractors in Boolean regulatory networks. 61
30823730 2019
34
[Successful treatment of pure red cell aplasia with cyclosporin in a patient with T-cell large granular lymphocytic leukemia harboring the STAT3 D661V mutation]. 61
30726823 2019
35
Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia. 61
29963929 2019
36
A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis. 61
30631033 2019
37
T-cell large granular lymphocytic (LGL) leukemia consists of CD4+/CD8dim and CD4-/CD8+ LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis. 61
31866622 2019
38
[Hepatocellular failure revealing T-cell large granular lymphocyte leukemia: Morocco case study and literature review]. 61
31934260 2019
39
Prevalence and Characteristics of Persistent Clonal T Cell Large Granular Lymphocyte Expansions in Rheumatoid Arthritis: A Comprehensive Analysis of 529 Patients. 61
29938921 2018
40
Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. 61
30455079 2018
41
Does it take three to tango? An unsuspected multimorbidity of CD8+ T cell lymphoproliferative disorder, malaria, and EBV infection. 61
30290813 2018
42
Large granular lymphocytic leukemia CD3-CD56-: a challenge for the biologist and the physician. 61
30078779 2018
43
Management of T-cell large granular lymphocyte leukemia and concurrent retroperitoneal liposarcoma. 61
30057739 2018
44
Pure red cell aplasia with t-cell large granular lymphocytic leukemia. 61
29921385 2018
45
Mutations in the signal transducer and activator of transcription family of genes in cancer. 61
29417693 2018
46
Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia. 61
29269802 2018
47
Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. 61
29474442 2018
48
T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas: A Study From the Bone Marrow Pathology Group. 61
29365010 2018
49
Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging. 61
29559980 2018
50
Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL). 61
29281994 2017

Variations for T-Cell Large Granular Lymphocyte Leukemia

Expression for T-Cell Large Granular Lymphocyte Leukemia

Search GEO for disease gene expression data for T-Cell Large Granular Lymphocyte Leukemia.

Pathways for T-Cell Large Granular Lymphocyte Leukemia

Pathways related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 STAT5B STAT3 NCAM1 KLRK1 KLRD1 KIR2DL3
2
Show member pathways
13.8 STAT5B STAT3 IL2RB IL2RA IL2 IL18
3
Show member pathways
13.66 STAT5B STAT3 IL2RB IL2RA IL2 IL18
4
Show member pathways
13.4 STAT5B STAT3 IL2RB IL2RA IL2 IL18
5
Show member pathways
13.32 STAT5B STAT3 NCAM1 IL2RB IL2RA IL2
6
Show member pathways
13.28 IL2RB IL2RA IL2 IL18 IL15RA FASLG
7 12.85 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
8
Show member pathways
12.84 KLRD1 KIR2DL3 KIR2DL1 IL2RA IL2 IL15RA
9
Show member pathways
12.83 STAT5B STAT3 IL2RB IL2RA IL2 IL18
10
Show member pathways
12.78 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
11
Show member pathways
12.61 STAT5B STAT3 IL2RB IL2RA IL2 IL18
12
Show member pathways
12.45 KLRK1 KLRD1 KIR2DL3 KIR2DL1 IL2 GZMB
13 12.42 STAT5B STAT3 NCAM1 IL2RB IL2RA IL2
14
Show member pathways
12.37 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
15 12.35 STAT5B IL2RB IL2RA IL2 IL15RA CSF2
16
Show member pathways
12.31 IL2RB IL2RA IL2 IL18
17
Show member pathways
12.12 IL2RB IL2RA IL2 CSF2
18
Show member pathways
12.09 STAT5B STAT3 IL2RB IL2RA IL2
19 12.06 KLRK1 KLRD1 KIR2DL3 KIR2DL1
20 11.95 NCAM1 KLRK1 IL2RB IL2RA IL2 CSF2
21 11.92 STAT3 IL18 FASLG
22
Show member pathways
11.82 STAT5B STAT3 GZMB
23
Show member pathways
11.81 STAT3 IL2RB IL2RA IL2 IL18 GZMB
24
Show member pathways
11.79 STAT5B STAT3 IL2 IL18
25
Show member pathways
11.79 IL2RA IL2 FASLG CSF2
26 11.77 STAT5B IL2 CSF2
27 11.72 NCAM1 IL2 CSF2
28
Show member pathways
11.7 STAT5B IL2RB IL2RA IL2 FASLG
29 11.67 STAT5B STAT3 CSF2
30 11.66 STAT5B STAT3 IL2RB IL2RA IL2 IL15RA
31
Show member pathways
11.64 IL2RB IL2RA IL2 GZMB FASLG
32
Show member pathways
11.56 GZMK GZMB GZMA
33 11.52 STAT3 IL18 CSF2
34 11.5 STAT5B STAT3 IL2RA
35 11.49 IL2RB IL2RA IL2
36
Show member pathways
11.46 STAT5B STAT3 IL2RA
37 11.32 IL2RB IL2RA IL2
38 11.27 STAT3 IL2RA IL2 IL18
39
Show member pathways
11.26 STAT5B STAT3 IL2RA
40
Show member pathways
11.24 STAT5B IL2RB IL2RA IL2
41 11.23 NCAM1 KLRK1 KLRD1 IL2RB IL2RA IL2
42
Show member pathways
11.11 IL2RB IL2RA IL2 IL15RA GZMB GZMA
43 10.8 STAT3 CSF2

GO Terms for T-Cell Large Granular Lymphocyte Leukemia

Cellular components related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.65 NCAM1 KLRK1 IL2RB IL2RA FASLG
2 extracellular region GO:0005576 9.65 NCAM1 IL2 IL18 IL15RA GZMK GZMB
3 cell surface GO:0009986 9.63 NCAM1 KLRK1 IL2RB IL2RA IL15RA FASLG
4 interleukin-2 receptor complex GO:0005893 8.62 IL2RB IL2RA

Biological processes related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 STAT5B STAT3 IL2 FASLG CSF2
2 regulation of immune response GO:0050776 9.86 KLRK1 KLRD1 KIR2DL3 KIR2DL1
3 immune response GO:0006955 9.86 KIR2DL3 KIR2DL1 IL2RA IL2 IL18 GZMA
4 MAPK cascade GO:0000165 9.85 NCAM1 IL2RB IL2RA IL2 IL18 CSF2
5 positive regulation of inflammatory response GO:0050729 9.76 STAT5B IL2 IL18
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 STAT3 IL2 IL18 CSF2
7 positive regulation of natural killer cell mediated cytotoxicity GO:0045954 9.65 STAT5B KLRK1 KLRD1
8 natural killer cell activation GO:0030101 9.63 KLRK1 IL2 IL18
9 positive regulation of activated T cell proliferation GO:0042104 9.62 STAT5B IL2RA IL2 IL18
10 pyroptosis GO:0070269 9.61 GZMB GZMA
11 positive regulation of interleukin-17 production GO:0032740 9.61 IL2 IL18
12 natural killer cell mediated cytotoxicity GO:0042267 9.61 KLRK1 IL18 GZMB
13 regulation of regulatory T cell differentiation GO:0045589 9.6 IL2RA IL2
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.59 STAT5B STAT3
15 interleukin-9-mediated signaling pathway GO:0038113 9.57 STAT5B STAT3
16 positive regulation of natural killer cell proliferation GO:0032819 9.55 STAT5B IL18
17 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2RA IL2
18 positive regulation of tissue remodeling GO:0034105 9.52 IL2 IL18
19 neutrophil differentiation GO:0030223 9.51 LBR CSF2
20 regulation of T cell homeostatic proliferation GO:0046013 9.49 IL2RA IL2
21 interleukin-15-mediated signaling pathway GO:0035723 9.46 STAT5B STAT3 IL2RB IL15RA
22 interleukin-2-mediated signaling pathway GO:0038110 9.26 STAT5B IL2RB IL2RA IL2
23 cytokine-mediated signaling pathway GO:0019221 9.23 STAT5B STAT3 IL2RB IL2RA IL2 IL18

Molecular functions related to T-Cell Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 STAT5B STAT3 NCAM1 LBR KLRK1 KLRD1
2 cytokine activity GO:0005125 9.62 IL2 IL18 FASLG CSF2
3 glucocorticoid receptor binding GO:0035259 9.37 STAT5B STAT3
4 interleukin-15 receptor activity GO:0042010 9.16 IL2RB IL15RA
5 interleukin-2 binding GO:0019976 8.96 IL2RB IL2RA
6 interleukin-2 receptor activity GO:0004911 8.62 IL2RB IL2RA

Sources for T-Cell Large Granular Lymphocyte Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....